NCT05699408View on ClinicalTrials.gov

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

November 23, 2024

Study Completion Date

November 23, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

INS068 injection

INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial

DRUG

Insulin Glargine

Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY